PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
No Data
No Data available this quarter, please select a different quarter.
6.30
Higher net debt at 1.1-1.25x AVXL's 5.23. Bruce Berkowitz would look for hidden assets justifying this higher leverage.
-7890.84
Negative coverage while AVXL shows 0.00. Joel Greenblatt would look for operating improvements and turnaround potential.
11.56
Current ratio 1.25-1.5x AVXL's 8.03. Mohnish Pabrai would examine if this strength creates buying power advantages.
No Data
No Data available this quarter, please select a different quarter.